Executive Summary Ecstasy Sample Characteristics Methamphetamine Non-Prescribed Pharmaceutical Stimulants

In 2023, the majority three substances remained low in 2023, at a (86%) of the sample reported recent cocaine median of five days or less in the preceding six use (86% in 2022). [...] The perceived purity New Psychoactive Substances (NPS) and availability of cocaine remained stable in In 2023, 13% of the sample reported recent 2023 with the largest per cent perceiving use of any NPS (including plant-based NPS) cocaine to be of ‘low’ purity (40%; 43% in 2022) (12% in 2022) and 11% reported recent use of and ‘very easy’ to obtain (51%; 51% in 2022). [...] who had recently used non-prescribed Recent use of non-prescribed e-cigarettes cannabis and/or cannabinoid-related products significantly increased from 61% in 2022 to in 2023 reported smoking as a route of 76% in 2023 (p=0.035), with more participants administration (87% in 2022), with significantly reporting daily use in 2023 (49%; 27% in 2022; fewer participants reporting p=0.003). [...] 2 Ecstasy and Related Drugs Reporting System 2023 Drug-Related Harms and Other o Twenty-eight per cent of the sample Behaviours reported accessing any health service for alcohol and/or drug support in the six o On the last occasion of ecstasy or related months preceding interview (19% in 2022), drug use, the majority (86%) of the sample and almost one quarter (24%) of the sample reported concurren. [...] o There were significant differences in modes o Four fifths (81%) of the sample reported of purchasing illicit or non-prescribed drugs engaging in some form of sexual activity in in the past 12 months in 2023.